SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Auna S.A. | ||||
| By: | /s/ Gisele Remy | |||
| Name: | Gisele Remy | |||
| Title: | Chief Financial Officer | |||
Date: October 28, 2025
Auna S.A. and Subsidiaries Condensed Consolidated Interim Financial Statements June 30, 2025 |
Contents |
Page |
|||
Condensed Consolidated Interim Statement of Financial Position |
1 | |||
Condensed Consolidated Interim Statement of Profit of Loss and Other Comprehensive Income |
2 | |||
Condensed Consolidated Interim Statement of Changes in Equity |
3 | |||
Condensed Consolidated Interim Statement of Cash Flows |
4 | |||
Notes to the Condensed Consolidated Interim Financial Statements |
5 - 48 |
|||
In thousands of soles |
Note |
June 30, 2025 |
December 31, 2024 |
In thousands of soles |
Note |
June 30, 2025 |
December 31, 2024 |
|||||||||||||||||||||||
Assets |
Liabilities |
|||||||||||||||||||||||||||||
Current assets |
Current liabilities |
|||||||||||||||||||||||||||||
Cash and cash equivalents |
Loans and borrowings | 9 |
||||||||||||||||||||||||||||
Trade accounts receivable |
4 |
Lease liabilities | 8 |
|||||||||||||||||||||||||||
Other assets |
Trade accounts payable | 10 |
||||||||||||||||||||||||||||
Inventories |
Other accounts payable | |||||||||||||||||||||||||||||
Derivative financial instruments |
5 |
Provisions | 11 |
|||||||||||||||||||||||||||
Other investments |
Derivative financial instruments | 5 |
||||||||||||||||||||||||||||
Total current assets |
Insurance contract liabilities | 12 |
||||||||||||||||||||||||||||
| Deferred income | ||||||||||||||||||||||||||||||
Non-current assets |
Total current liabilities |
|||||||||||||||||||||||||||||
Trade accounts receivable |
4 |
|||||||||||||||||||||||||||||
Other assets |
Non-current liabilities |
|||||||||||||||||||||||||||||
Investments in associates and joint venture |
Loans and borrowings | 9 |
||||||||||||||||||||||||||||
Other investments |
Lease liabilities | 8 |
||||||||||||||||||||||||||||
Property, furniture, and equipment |
6 |
Trade accounts payable | 10 |
|||||||||||||||||||||||||||
Intangible assets |
7 |
Other accounts payable | ||||||||||||||||||||||||||||
Right-of-use |
8 |
Derivative financial instruments | 5 |
|||||||||||||||||||||||||||
Investment properties |
Deferred tax liabilities | |||||||||||||||||||||||||||||
Derivative financial instruments |
5 |
Deferred income | ||||||||||||||||||||||||||||
Deferred tax assets |
Total non-current liabilities |
|||||||||||||||||||||||||||||
Total non-current assets |
Total liabilities |
|||||||||||||||||||||||||||||
Equity |
13 |
|||||||||||||||||||||||||||||
| Share capital | ||||||||||||||||||||||||||||||
| Share premium | ||||||||||||||||||||||||||||||
| Reserves | ||||||||||||||||||||||||||||||
| Retained losses | ( |
) | ( |
) | ||||||||||||||||||||||||||
Equity attributable to the owner of the Company |
||||||||||||||||||||||||||||||
Non-controlling interest |
||||||||||||||||||||||||||||||
Total equity |
||||||||||||||||||||||||||||||
Total assets |
Total liabilities and equity |
|||||||||||||||||||||||||||||
In thousands of soles |
Note |
Three-month period ended June 30 |
Six-month periodended June 30 |
|||||||||||||||||
2025 |
2024 |
2025 |
2024 |
|||||||||||||||||
Revenue |
||||||||||||||||||||
Insurance revenue |
14 |
|||||||||||||||||||
Healthcare services revenue |
14 |
|||||||||||||||||||
Sale of medicines |
14 |
|||||||||||||||||||
Total revenue from contracts with customers |
||||||||||||||||||||
Cost of sales and services |
15 |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||
Gross profit |
||||||||||||||||||||
Selling expenses |
15 |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||
Administrative expenses |
15 |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||
(Loss) reversal for impairment of trade receivables |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Other income |
||||||||||||||||||||
Operating profit |
||||||||||||||||||||
Finance income |
||||||||||||||||||||
Finance income from exchange difference |
||||||||||||||||||||
Finance costs |
16 |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||
Finance costs from exchange difference |
16 |
( |
) | ( |
) | |||||||||||||||
Net finance cost |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||
Share of profit of equity-accounted investees |
||||||||||||||||||||
Profit before tax |
||||||||||||||||||||
Income tax (expense) benefit |
18 |
( |
) | ( |
) | ( |
) | |||||||||||||
Profit (loss) for the period |
( |
) | ||||||||||||||||||
Other comprehensive income (loss) |
||||||||||||||||||||
Items that are or may be reclassified subsequently to profit or loss |
||||||||||||||||||||
Cash flow hedges |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Foreign operations – foreign currency translation differences |
( |
) | ( |
) | ||||||||||||||||
Other investments at FVOCI – net change in fair value |
( |
) | ||||||||||||||||||
Income tax |
||||||||||||||||||||
Other comprehensive income (loss) for the period, net of tax |
( |
) |
( |
) | ||||||||||||||||
Total comprehensive income (loss) for the period |
( |
) |
( |
) | ||||||||||||||||
Income (loss) attributable to: |
||||||||||||||||||||
Owner of the Company |
( |
) | ||||||||||||||||||
Non-controlling interest |
||||||||||||||||||||
( |
) | |||||||||||||||||||
Total comprehensive income (loss) attributable to: |
||||||||||||||||||||
Owner of the Company |
( |
) | ( |
) | ||||||||||||||||
Non-controlling interest |
( |
) | ||||||||||||||||||
( |
) |
( |
) | |||||||||||||||||
Earnings per share |
||||||||||||||||||||
Basic earnings per share |
( |
) | ||||||||||||||||||
Diluted earnings per share |
( |
) | ||||||||||||||||||
Equity attributable to the owner of the Company |
||||||||||||||||||||||||||||||||||||||||||||||||||||
In thousands of soles |
Note |
Share capital (note 13.A) |
Share premium |
Other capital reserve |
Translation reserve (note 13.B) |
Cost of hedging reserve (note 13.C) |
Hedging reserve (note 13.D) |
Merger and other reserves |
Shared- based payment reserve (note 22) |
Retained (losses) earnings |
Total |
Non- controlling interest |
Total equity |
|||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2023 |
- |
( |
) |
- |
( |
) |
||||||||||||||||||||||||||||||||||||||||||||||
Balances as of January 1, 2024 |
- |
( |
) |
- |
( |
) |
||||||||||||||||||||||||||||||||||||||||||||||
Profit (loss) for the period |
- | - | - | - | - | - | - | - | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) for the period |
- | - | - | ( |
) | ( |
) | - | - | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Total comprehensive income (loss) for the period |
- |
- |
( |
) |
( |
) |
- |
( |
) |
( |
) |
( |
) | |||||||||||||||||||||||||||||||||||||||
Issuance of common stock, net of issuance costs |
- | - | - | - | - |
- | - | - | ||||||||||||||||||||||||||||||||||||||||||||
Capitalization of merger reserve |
- | - | - | - | - | ( |
) | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
Acquisition of non-controlling interest |
- | - | - | - | - | ( |
) | - | - | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Change in fair value of put and call liability |
- | - | - | - | - | - | ( |
) | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||||||||||||
Equity-settled share-based payment |
- | - | - | - | - | - | - |
- | - | |||||||||||||||||||||||||||||||||||||||||||
Total transactions with the owner of the Company |
- |
- |
- |
( |
) |
- |
( |
) |
( |
) | ||||||||||||||||||||||||||||||||||||||||||
Balances as of June 30, 2024 |
( |
) |
- |
( |
) |
|||||||||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2024 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||||||||||||
Profit for the period |
- | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income for the period |
- | - | - | ( |
) | - | ||||||||||||||||||||||||||||||||||||||||||||||
Total comprehensive income for the period |
- |
- |
- |
( |
) |
- |
||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares |
- | - | - | - | - | ( |
) | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||
Equity-settled share-based payment |
22 |
- | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
Total transactions with the owner of the Company |
- |
- |
- |
- |
- |
- |
- |
|||||||||||||||||||||||||||||||||||||||||||||
Balances as of June 30, 2025 |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||||||||||
Six-month period ended June 30 |
||||||||||
In thousands of soles |
Note |
2025 |
2024 |
|||||||
Cash flows from operating activities |
||||||||||
Profit (loss) for the period |
( |
) | ||||||||
Adjustments for: |
||||||||||
Depreciation |
6 |
|||||||||
Depreciation of right-of-use |
8 |
|||||||||
Amortization |
7 |
|||||||||
(Reversal) Impairment of inventories |
( |
) | ||||||||
Equity-settled share-based payment transactions |
||||||||||
Gain on disposal of property, furniture, and equipment |
||||||||||
Gain on disposal of right-of-use |
||||||||||
Loss on disposal of intangibles |
||||||||||
(Reversal) Impairment of trade receivables |
||||||||||
Share of profit of equity-accounted investees |
( |
) | ( |
) | ||||||
Provisions |
11 |
|||||||||
Finance income |
( |
) | ( |
) | ||||||
Finance costs |
16 |
|||||||||
Tax expense |
||||||||||
Net changes in assets and liabilities: |
||||||||||
Trade accounts receivable and other assets |
( |
) | ( |
) | ||||||
Inventories |
||||||||||
Trade accounts payable and other accounts payable |
( |
) | ||||||||
Provisions and employee benefits |
11 |
( |
) | ( |
) | |||||
Insurance contract liabilities |
12 |
|||||||||
Cash generated from operating activities |
||||||||||
Income tax paid |
( |
) | ( |
) | ||||||
Interest received |
||||||||||
Net cash from operating activities |
||||||||||
Cash flows from investing activities |
||||||||||
Payment for accounts payable to former shareholder |
( |
) | ||||||||
Purchase of properties, furniture, and equipment |
6 |
( |
) | ( |
) | |||||
Proceeds from sale of property, furniture, and equipment |
||||||||||
Purchase of intangibles |
7 |
( |
) | ( |
) | |||||
Dividends from equity-accounted investees |
||||||||||
Purchase of other investments, net of sales |
( |
) | ( |
) | ||||||
Payment for contingent consideration |
( |
) | ||||||||
Net cash used in investing activities |
( |
) |
( |
) | ||||||
Cash flows from financing activities |
||||||||||
Proceeds from issuance of common stock in initial public offering, net of issuance costs |
||||||||||
Payments of initial public offering costs |
( |
) | ||||||||
Proceeds from loans and borrowings |
9 |
|||||||||
Payment for loans and borrowings |
9 |
( |
) | ( |
) | |||||
Payment for lease liabilities |
8 |
( |
) | ( |
) | |||||
Penalty paid for debt prepayment |
( |
) | ||||||||
Payment for derivatives premiums |
( |
) | ( |
) | ||||||
Payment for costs of extinguishment of debt |
9 |
( |
) | |||||||
Interest paid |
9 |
( |
) | ( |
) | |||||
Proceeds from settlement of derivatives - interest rate swaps |
( |
) | ||||||||
Acquisition of non-controlling interest |
( |
) | ||||||||
Net cash used in financing activities |
( |
) |
( |
) | ||||||
Net (decrease) increase in cash and cash equivalents |
( |
) | ( |
) | ||||||
Cash and cash equivalents at January 1 |
||||||||||
Effect of movements in exchange rates on cash held |
( |
) | ||||||||
Cash and cash equivalents at June 30 |
||||||||||
Transactions not representing cash flows |
||||||||||
Assets acquired through finance lease and other financing |
8 |
|||||||||
Assets acquired from suppliers in installments |
( |
) | ||||||||
1. |
Economic Activity |
A. |
Business activity |
B. |
Regulatory agency for private healthcare services |
2. |
Basis for the Preparation of Condensed Consolidated Interim Financial Statements |
A. |
Basis of accounting |
B. |
Basis of measurement |
C. |
Functional and presentation currency |
3. |
Use of Judgments and Estimates |
| Level 1: | Quoted prices (unadjusted) in active markets for identical assets or liabilities. |
| Level 2: | Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices). |
| Level 3: | Inputs for the asset or liability that are not based on observable market data (unobservable inputs). |
4. |
Trade Accounts Receivable |
In thousands of soles |
2025 |
2024 |
||||||
Trade accounts receivable |
||||||||
Trade accounts receivable from related parties |
||||||||
Less: Loss for impairment of trade receivable |
( |
) | ( |
) | ||||
Current |
||||||||
Non-current |
||||||||
i. |
Disaggregation of trade accounts receivable |
In thousands of soles |
2025 |
2024 |
||||||
Healthcare services |
||||||||
ii. |
By primary geographical markets and type of service |
In thousands of soles |
Peru |
Colombia |
Mexico |
Total |
||||||||||||
Healthcare services |
||||||||||||||||
In thousands of soles |
Peru |
Colombia |
Mexico |
Total |
||||||||||||
Healthcare services |
||||||||||||||||
| In thousands of soles |
Peru |
Colombia |
Mexico |
Total |
||||||||||||
| Current (not past due) |
||||||||||||||||
| 1 - 90 days past due |
||||||||||||||||
| 91 - 180 days past due |
||||||||||||||||
| 181 - 360 days past due |
||||||||||||||||
| More than 360 days past due |
||||||||||||||||
| As of December 31, 2024 |
| |||||||||||||||
| In thousands of soles |
Peru |
Colombia |
Mexico |
Total |
||||||||||||
| Current (not past due) |
||||||||||||||||
| 1 - 90 days past due |
||||||||||||||||
| 91 - 180 days past due |
||||||||||||||||
| 181 - 360 days past due |
||||||||||||||||
| More than 360 days past due |
||||||||||||||||
| Expected credit loss assessment for corporate customers The following table provides information about the exposure to credit risk and Expected Credit Losses (ECLs) for trade receivables and contract assets for corporate customers as of June 30, 2025: |
| |||||||||||||||
| In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||||||
| Current (not past due) |
||||||||||||||||
| 1 - 90 days past due |
||||||||||||||||
| 91 - 180 days past due |
||||||||||||||||
| 181 - 360 days past due |
||||||||||||||||
| More than 360 days past due |
||||||||||||||||
| The following table provides information about the exposure to credit risk and ECLs for trade receivables and contract assets for corporate customers as of December 31, 2024: |
| |||||||||||||||
| In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||||||
| Current (not past due) |
||||||||||||||||
| 1 - 90 days past due |
||||||||||||||||
| 91 - 180 days past due |
||||||||||||||||
| 181 - 360 days past due |
||||||||||||||||
| More than 360 days past du e |
||||||||||||||||
Expected credit loss assessment for individual custom ers The following table provides information about the exposure to credit risk and ECLs for trade receivables and contract assets from individual customers (patients) as of June 30, 2025: |
||||||||||||||||
In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||||||
Current (not past due) |
||||||||||||||||
1 - 90 days past due |
||||||||||||||||
91 - 180 days past due |
||||||||||||||||
181 - 360 days past due |
||||||||||||||||
More than 360 days past due |
||||||||||||||||
The following table provides information about the exposure to credit risk and ECLs for trade receivables and contract assets from individual customers (patients) as of December 31, 2024: |
||||||||||||||||
In thousands of soles |
Weighted- average loss rate |
Gross carrying amount |
Loss allowance |
|||||||||||||
Current (not past due) |
||||||||||||||||
1 - 90 days past due |
||||||||||||||||
91 - 180 days past due |
||||||||||||||||
181 - 360 days past due |
||||||||||||||||
More than 360 days past due |
||||||||||||||||
5. |
Derivative Financial Instruments |
In thousands of soles |
Reference value |
Maturity date |
2025 |
2024 |
||||||||||||||||
Derivative assets mandatorily measured at FVOCI |
||||||||||||||||||||
Fx operation Agreement – Call Spread |
(a | ) | US$ |
|||||||||||||||||
Fx operation Agreement – Call Spread (Long Put) |
(a | ) | US$ |
( |
) | |||||||||||||||
Fx operation Agreement – Call Spread (Short Call) |
(a | ) | US$ |
|||||||||||||||||
Fx operation Agreement – Call Spread |
(b | ) | US$ |
|||||||||||||||||
Fx operation Agreement – Single Call |
(c | ) | US$ |
|||||||||||||||||
Fx operation Agreement – Call Spread |
(d | ) | US$ |
|||||||||||||||||
Fx operation Agreement – Call Spread |
(d | ) | US$ |
|||||||||||||||||
Fx operation Agreement – Call Spread |
(e | ) | US$ |
|||||||||||||||||
Interest Rate Swap – TIIE |
(f | ) | MXN |
|||||||||||||||||
Current |
||||||||||||||||||||
Non-current |
||||||||||||||||||||
In thousands of soles |
Reference value |
Maturity date |
2025 |
2024 |
||||||||||||||||
Derivative liabilities mandatorily measured at FVTPL |
||||||||||||||||||||
Fx operation Agreement – Forward |
(g | ) | US$ |
- | ||||||||||||||||
Derivative liabilities mandatorily measured at FVOCI |
||||||||||||||||||||
Fx operation Agreement – Call Spread (Long Put) |
(a | ) | US$ |
|||||||||||||||||
Fx operation Agreement – Call Spread (Short Call) |
(a | ) | US$ |
( |
) | - | ||||||||||||||
Interest Rate Swap – TIIE |
(f | ) | MXN |
|||||||||||||||||
Interest Rate Swap – SOFR |
(f | ) | US$ |
|||||||||||||||||
Interest Rate Swap – TIIE |
(f | ) | MXN |
- | ||||||||||||||||
Current |
||||||||||||||||||||
Non-current |
||||||||||||||||||||
| (a) | On December 18, 2023, new senior notes maturing in 2029 were issued in exchange for a part of the previous senior notes that were canceled in the exchange and this derivate instrument was designated as a hedge to cover both senior notes up to the reference value. |
| (b) | On January 23, 2025, the Group signed foreign exchange options which included a Call spread agreement with Citibank for US$ |
| (c) | On May 5, 2023, the Group, through its subsidiary Grupo Salud Auna Mexico, signed foreign exchange options which included a Single call agreement with Santander Bank for US$ |
| (d) | On June 1, 2023, the Group signed foreign exchange options which included a Call spread agreement with Citibank for US$ |
| (e) | On November 29, 2022, the Group signed a new foreign exchange options which included Call spread agreement with Citibank N.A. for S/ |
| (f) | In April 2024, the Group signed new interest rate swap agreements to cover the interest rate fluctuation related to the new term loan signed December 18, 2023. The amount covered was MXN |
| (g) | In June 2025, the Group signed a foreign exchange forward for US$ |
6. |
Property, Furniture, and Equipment |
In thousands of soles |
2025 |
2024 |
||||||
Cost |
||||||||
Balances as of January 1, |
||||||||
Additions (a) |
||||||||
Exchange difference |
( |
) | ||||||
Transfers from right of use of assets |
- | |||||||
Disposals |
( |
) | ( |
) | ||||
Write-off |
( |
) | ( |
) | ||||
Reclassifications from intangibles assets |
( |
) | ||||||
Balances as of June 30, |
||||||||
Accumulated depreciation |
||||||||
Balances as of January 1, |
( |
) | ( |
) | ||||
Additions |
( |
) | ( |
) | ||||
Exchange difference |
( |
) | ||||||
Transfers from right of use of assets |
- | ( |
) | |||||
Disposals |
||||||||
Write-off |
||||||||
Balances as of June 30, |
( |
) |
( |
) | ||||
Carrying amount |
||||||||
Balances as of January 1, |
||||||||
Balances as of June 30, |
||||||||
| (a) | During the six months ended June 30, 2025, the Group acquired assets with a cost of S/ |
7. |
Intangible Assets |
In thousands of soles |
2025 |
2024 |
||||||
Cost |
||||||||
Balances as of January 1 |
||||||||
Additions (a) |
||||||||
Reclassifications to property, furniture and equipment |
- | ( |
) | |||||
Write-off |
- | ( |
) | |||||
Exchange difference |
( |
) | ||||||
Balances as of June 30 |
||||||||
In thousands of soles |
2025 |
2024 |
||||||
Accumulated amortization |
||||||||
Balances as of January 1 |
( |
) | ( |
) | ||||
Additions |
( |
) | ( |
) | ||||
Exchange difference |
( |
) | ||||||
Balances as of June 30 |
( |
) |
( |
) | ||||
Carrying amount |
||||||||
Balances as of January 1 |
||||||||
Balances as of June 30 |
||||||||
| (a) | During the six months ended June 30, 2025, the Group acquired intangible assets mainly related to software, SAP licenses and trademark with a cost of S/ |
In thousands of soles |
2025 |
2024 |
||||||
Cost |
||||||||
Balances as of January 1, |
||||||||
Exchange difference |
( |
) | ||||||
Balances as of June 30, |
||||||||
Carrying amount |
||||||||
Balances as of January 1, |
||||||||
Balances as of June 30, |
||||||||
8. |
Leases |
Right-of-use assets |
||||||||
In thousands of soles |
2025 |
2024 |
||||||
Balances as of January 1, |
||||||||
Additions of right-of-use |
||||||||
Transfers to property, furniture and equipment net of depreciation |
- | ( |
) | |||||
Depreciation |
( |
) | ( |
) | ||||
Write-off (b) |
- | ( |
) | |||||
Exchange difference |
( |
) | ||||||
Balance as of June 30, |
||||||||
| (a) | During the six months ended June 30, 2025, the additions of the Group mainly corresponds to new lease agreements for use of commercial offices, health centers and equipment for medical use. The Group recognized S/ right-of-use right-of-use |
| (b) | During the six months ended June 30, 2024, the write-off corresponds to a medical equipment incident, which was compensated. |
Lease liabilities |
||||||||
In thousands of soles |
2025 |
2024 |
||||||
Balances as of January 1 |
||||||||
Additions |
||||||||
Interest expense |
||||||||
Payments |
( |
) | ( |
) | ||||
Exchange difference |
( |
) | ||||||
Balance as of June 30 |
||||||||
Current |
||||||||
Non-current |
||||||||
9. |
Loans and Borrowings |
2025 |
2024 |
|||||||||||||||||||||||||||||||
| In thousands of soles |
Type of obligation |
Maturity |
Interest rate |
Currency |
Face value |
Carrying amount |
Face value |
Carrying amount |
||||||||||||||||||||||||
| Entity |
||||||||||||||||||||||||||||||||
| Banco Davivienda |
Bank loan | |||||||||||||||||||||||||||||||
| Government | ||||||||||||||||||||||||||||||||
| guaranteed loan | ||||||||||||||||||||||||||||||||
| Bank loan | ||||||||||||||||||||||||||||||||
| Banco de Bogotá |
Bank loan | |||||||||||||||||||||||||||||||
| Banco de Occidente |
Bank loan | |||||||||||||||||||||||||||||||
2025 |
2024 |
|||||||||||||||||||||||||
In thousands of soles |
Type of obligation |
Maturity |
Interest rate |
Currency |
Face value |
Carrying amount |
Face value |
Carrying amount |
||||||||||||||||||
Bancolombia |
Bank loan | |
||||||||||||||||||||||||
| - | - | |||||||||||||||||||||||||
| - | ||||||||||||||||||||||||||
| - | ||||||||||||||||||||||||||
| - | ||||||||||||||||||||||||||
| Other financing | ||||||||||||||||||||||||||
Banco Citibank Colombia |
Bank loan | |||||||||||||||||||||||||
Itaú Corpbanca Colombia S.A. |
Bank loan | |||||||||||||||||||||||||
Boston Scientific Colombia lt |
Bank loan | |||||||||||||||||||||||||
Banco de Crédito del Perú |
Bank loan | |||||||||||||||||||||||||
Scotiabank Perú S.A.A. |
Other financing | |||||||||||||||||||||||||
| Bank loan | ||||||||||||||||||||||||||
Banco BBVA Continental |
Bank loan | |||||||||||||||||||||||||
2025 |
2024 |
|||||||||||||||||||||||||
In thousands of soles |
Type of obligation |
Maturity |
Interest rate |
Currency |
Face value |
Carrying amount |
Face value |
Carrying amount |
||||||||||||||||||
Banco Interamericano de Finanzas |
Bank loan | |||||||||||||||||||||||||
Banco Internacional del Perú S.A.A. |
Bank loan | |||||||||||||||||||||||||
Banco Pichincha |
Bank loan | |||||||||||||||||||||||||
Banco Citibank |
Bank loan | |||||||||||||||||||||||||
Banco GNB |
Bank loan | |||||||||||||||||||||||||
Secured bonds issues |
Senior notes | |||||||||||||||||||||||||
Banco Santander México, HSBC and Citibank |
Bank loan | |||||||||||||||||||||||||
HSBC México |
Bank loan |
|||||||||||||||||||||||||
Banco Santander España |
Bank loan | |||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||
Current |
- |
- |
||||||||||||||||||||||||
Non-current |
- |
- |
||||||||||||||||||||||||
In thousands of soles |
2025 |
2024 |
||||||
Balance as of January 1, |
||||||||
Changes in cash flows from financing |
||||||||
Proceeds from loans and borrowings |
||||||||
Payment for borrowings from financial obligations |
( |
) | ( |
) | ||||
Interest paid |
( |
) | ( |
) | ||||
Penalty paid for financial debt prepayment |
( |
) | - | |||||
Total changes from financing cash flows |
( |
) |
( |
) | ||||
Effect of changes in foreign exchange rates |
( |
) |
( |
) | ||||
Other changes |
||||||||
Interest expense |
||||||||
Transaction costs related to loans and borrowings |
( |
) | ( |
) | ||||
Financial debt prepayment penalty |
- | |||||||
Balance as of June 30, |
||||||||
◾ |
The Net Leverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is less than (i) to |
◾ |
The Interest Coverage Ratio for the Issuer and its Restricted Subsidiaries on a consolidated basis is at least i) |
◾ |
The consolidated leverage ratio is less than (i) |
◾ |
The consolidated interest coverage ratio is greater than (i) |
10. |
Trade Accounts Payable |
In thousands of soles |
2025 |
2024 |
||||||
Soles |
||||||||
US dollars |
||||||||
COP |
||||||||
MXN |
||||||||
Current |
||||||||
Non-current |
||||||||
11. |
Provisions |
In thousands of soles |
Outstanding claims reserve (i) |
Other provisions |
Total |
|||||||||
As of January 1, 2024 |
||||||||||||
Provision |
- | |||||||||||
Paid during the period |
( |
) | ( |
) | ( |
) | ||||||
Exchange difference |
- | ( |
) | ( |
) | |||||||
As of June 30, 2024 |
||||||||||||
As of January 1, 2025 |
||||||||||||
Provision |
- | |||||||||||
Paid during the period |
- | ( |
) | ( |
) | |||||||
Exchange difference |
- | |||||||||||
As of June 30, 2025 |
||||||||||||
| (i) | Outstanding claims reserve represent the Group’s outstanding third-party obligations and do not include amounts related to the Group’s customers that are part of the insurance premium program. |
12. |
Insurance Contract Liabilities |
2025 |
2024 |
|||||||||||||||||||||||||||||||
Liabilities for incurred claims |
Liabilities for incurred claims |
|||||||||||||||||||||||||||||||
In thousands of soles |
Liabilities for remaining coverage |
Estimates of present value of future cash flows |
Risk adjustment for non-financial risk |
Total |
Liabilities for remaining coverage |
Estimates of present value of future cash flows |
Risk adjustment for non-financial risk |
Total |
||||||||||||||||||||||||
Balances as of January 1 |
||||||||||||||||||||||||||||||||
Changes in the statement of profit or loss and OCI |
||||||||||||||||||||||||||||||||
Insurance revenue |
( |
) |
- |
- |
( |
) |
( |
) |
- |
- |
( |
) | ||||||||||||||||||||
Insurance service expenses |
||||||||||||||||||||||||||||||||
Incurred claims and other insurance service expenses |
- | - | - | - | ||||||||||||||||||||||||||||
Amortization of insurance acquisition cash flows |
- | - | - | - | ||||||||||||||||||||||||||||
Adjustments to liabilities for incurred claims |
- | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||
Total insurance service expenses |
( |
) |
||||||||||||||||||||||||||||||
Total insurance service result |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
Effect of movements in exchange rates |
( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||||||||||
Total changes in the statement of profit or loss and OCI |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
Cash flows |
||||||||||||||||||||||||||||||||
Premiums received |
- | - | - | - | ||||||||||||||||||||||||||||
Claims and other insurance service expenses paid |
- | ( |
) | - | ( |
) | - | ( |
) | - | ( |
) | ||||||||||||||||||||
Insurance acquisition cash flows |
( |
) | - | - | ( |
) | ( |
) | - | - | ( |
) | ||||||||||||||||||||
Total cash flows |
( |
) |
- |
( |
) |
- |
||||||||||||||||||||||||||
Acquired through business combinations |
- | - | - | - | - | |||||||||||||||||||||||||||
Closing assets |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||
Closing liabilities |
||||||||||||||||||||||||||||||||
Cost of sales and services (i) |
||||||||||||||||
Three-month period ended June 30 |
Six-month period ended June 30 |
|||||||||||||||
In thousands of soles |
2025 |
2024 |
2025 |
2024 |
||||||||||||
Medicines |
||||||||||||||||
Room service for inpatients |
||||||||||||||||
Medical consultation fees |
||||||||||||||||
Auxiliary services and clinical laboratory |
||||||||||||||||
Surgery fees |
||||||||||||||||
Insurance contracts |
( |
) | ||||||||||||||
| (i) | These expenses are included in the cost of sales and services in the condensed consolidated interim statement of profit or loss and other comprehensive income after deducting the margin mark-up. For the six-month period ended June 30, 2025 and 2024 the margin applied was calculated using the same basis as charged to third parties for these services and the overall average margin applied was |
13. |
Equity |
A. |
Share capital |
Range of shareholding percentage |
Number of shareholders |
Participation percentage | ||
From |
|
|||
From |
|
|||
From |
|
|||
From |
|
|||
B. |
Translation reserve |
C. |
Cost of hedging reserve |
D. |
Hedging reserve |
E. |
Non-controlling interests |
14. |
Revenue |
A. |
Disaggregation of revenue |
In thousands of soles |
Three-month period ended June 30 |
Six-month period ended June 30 |
||||||||||||||
2025 |
2024 |
2025 |
2024 |
|||||||||||||
Revenue from contracts with customers |
||||||||||||||||
Healthcare services (i) |
||||||||||||||||
Sale of medicines |
||||||||||||||||
Total revenue from contracts with customers |
||||||||||||||||
Insurance revenue |
||||||||||||||||
Total revenue |
||||||||||||||||
In thousands of soles |
Three-month period ended June 30 |
Six-month period ended June 30 |
||||||||||||||
2025 |
2024 |
2025 |
2024 |
|||||||||||||
Oncology plans |
||||||||||||||||
General healthcare services plans |
||||||||||||||||
Total insurance revenue |
||||||||||||||||
Timing of revenue recognition |
||||||||||||||||
Products transferred at a point in time |
||||||||||||||||
Products and services transferred over time |
||||||||||||||||
Total revenue from contracts with customers |
||||||||||||||||
| (i) | The amounts reported in Healthcare services revenue line item do not include revenue recognized for customers that are part of the Company’s insurance premium program. |
B. |
Disaggregation of revenue from contracts with customers |
Reportable segments |
||||||||||||
In thousands of soles |
Oncosalud Peru |
Healthcare services |
Total |
|||||||||
For the three months ended June 30, 2025 |
||||||||||||
Primary geographical markets |
||||||||||||
Peru |
||||||||||||
Colombia |
- | |||||||||||
Mexico |
- | |||||||||||
For the three months ended June 30, 2024 |
||||||||||||
Primary geographical markets |
||||||||||||
Peru |
||||||||||||
Colombia |
- | |||||||||||
Mexico |
- | |||||||||||
Reportable segments |
||||||||||||
In thousands of soles |
Oncosalud Peru |
Healthcare services |
Total |
|||||||||
For the six months ended June 30, 2025 |
||||||||||||
Primary geographical markets |
||||||||||||
Peru |
||||||||||||
Colombia |
- | |||||||||||
Mexico |
- | |||||||||||
For the six months ended June 30, 2024 |
||||||||||||
Primary geographical markets |
||||||||||||
Peru |
||||||||||||
Colombia |
- | |||||||||||
Mexico |
- | |||||||||||
| (i) | The reportable segments correspond to each different location (see Note 17). |
C. |
Contract balances |
In thousands of soles |
Note |
2025 |
2024 |
|||||||
Trade accounts receivable |
4 |
|||||||||
Contract liabilities, which are included in “trade accounts payable” |
10 |
( |
) | ( |
) | |||||
15. |
Cost of Sales and Services, Selling Expenses and Administrative Expenses |
Cost of sales and services |
Selling expenses |
Administrative expenses |
Total |
|||||||||||||||||||||||||||||||
In thousands of soles |
Note |
June 30, 2025 |
June 30, 2024 |
June 30, 2025 |
June 30, 2024 |
June 30, 2025 |
June 30, 2024 |
June 30, 2025 |
June 30, 2024 |
|||||||||||||||||||||||||
Medicines |
||||||||||||||||||||||||||||||||||
Auxiliary services and clinical laboratory |
||||||||||||||||||||||||||||||||||
Room service for inpatients |
||||||||||||||||||||||||||||||||||
Surgery fees |
||||||||||||||||||||||||||||||||||
Medical consultation fees |
||||||||||||||||||||||||||||||||||
Insurance contracts |
||||||||||||||||||||||||||||||||||
Personnel expenses (a) |
||||||||||||||||||||||||||||||||||
Services provided by third parties (b) |
||||||||||||||||||||||||||||||||||
Depreciation |
6 and 8 |
|||||||||||||||||||||||||||||||||
Amortization |
7 |
|||||||||||||||||||||||||||||||||
Other management charges |
||||||||||||||||||||||||||||||||||
Tax expenses |
||||||||||||||||||||||||||||||||||
Cost of sales and services |
Selling expenses |
Administrative expenses |
Total |
|||||||||||||||||||||||||||||||||
In thousands of soles |
Note |
June 30, 2025 |
June 30, 2024 |
June 30, 2025 |
June 30, 2024 |
June 30, 2025 |
June 30, 2024 |
June 30, 2025 |
June 30, 2024 |
|||||||||||||||||||||||||||
Medicines |
||||||||||||||||||||||||||||||||||||
Auxiliary services and clinical laboratory |
||||||||||||||||||||||||||||||||||||
Room service for inpatients |
||||||||||||||||||||||||||||||||||||
Surgery fees |
||||||||||||||||||||||||||||||||||||
Medical consultation fees |
||||||||||||||||||||||||||||||||||||
Insurance contracts |
||||||||||||||||||||||||||||||||||||
Personnel expenses (a) |
||||||||||||||||||||||||||||||||||||
Services provided by third parties (b) |
||||||||||||||||||||||||||||||||||||
Depreciation |
6 and 8 |
|||||||||||||||||||||||||||||||||||
Amortization |
7 |
|||||||||||||||||||||||||||||||||||
Other management charges |
||||||||||||||||||||||||||||||||||||
Tax expenses |
||||||||||||||||||||||||||||||||||||
| (a) | Personnel expenses comprise the following: |
Three-month period ended June 30 |
Six-month period ended June 30 |
|||||||||||||||
In thousands of soles |
2025 |
2024 |
2025 |
2024 |
||||||||||||
Remunerations |
||||||||||||||||
Legal bonuses |
||||||||||||||||
Health insurance for employees |
||||||||||||||||
Severance payment |
||||||||||||||||
Vacations |
||||||||||||||||
Bonuses |
||||||||||||||||
Employees’ profit sharing |
||||||||||||||||
Board of Directors’ remuneration |
||||||||||||||||
Equity-settled share-based payment expenses |
||||||||||||||||
Compensation to personnel |
||||||||||||||||
Training |
||||||||||||||||
Other benefits |
||||||||||||||||
| (b) | Services provided by third parties include the following: |
Three-month period ended June 30 |
Six-month period ended June 30 |
|||||||||||||||
In thousands of soles |
2025 |
2024 |
2025 |
2024 |
||||||||||||
Sales commission |
||||||||||||||||
Advisory and consulting fees |
||||||||||||||||
Utilities |
||||||||||||||||
Service and repair |
||||||||||||||||
Leases |
||||||||||||||||
Credit card commission |
||||||||||||||||
Custodial and cleaning services |
||||||||||||||||
Advertisement |
||||||||||||||||
Hosting |
||||||||||||||||
Collection expenses |
||||||||||||||||
Travel and entertainment expenses |
||||||||||||||||
Others |
||||||||||||||||
16. |
Finance Costs |
Three-month period ended June 30 |
Six-month periodended June 30 |
|||||||||||||||||||
In thousands of soles |
Note |
2025 |
2024 |
2025 |
2024 |
|||||||||||||||
Financial liabilities measured at amortized cost – interest expense |
||||||||||||||||||||
Interest from leases liabilities |
||||||||||||||||||||
Financial assets at FVTPL – net change in fair value: Derivative Assets mandatorily measured at FVTPL |
( |
) | ||||||||||||||||||
Exchange difference |
- | - | ||||||||||||||||||
Cash flow hedges – reclassified from OCI for costs of hedging reserve |
||||||||||||||||||||
Unwind of derivative financial instruments measured at FVOCI |
- | - | ||||||||||||||||||
Change in fair value of contingent consideration |
- | - | ||||||||||||||||||
Cash flow hedges settlement - Swaps |
- | - | ||||||||||||||||||
Financial debt prepayment penalty |
9 |
- | - | |||||||||||||||||
Others (a) |
||||||||||||||||||||
| (a) | For the six-months periods ended June 30, 2025 and 2024, include mainly cost of factoring for S/ |
17. |
Operating Segments |
A. |
Basis for segmentation |
Reportable segments |
Operations | |
B. |
Information about reportable segments |
In thousands of soles |
Reportable segments |
|||||||||||||||||||||||||||
| Oncosalud Peru |
Healthcare services in Peru |
Healthcare services in Colombia |
Healthcare services in Mexico |
Total reportable segments |
Holding and eliminations |
Total |
||||||||||||||||||||||
| 2025 |
||||||||||||||||||||||||||||
| External revenues |
- | |||||||||||||||||||||||||||
| Inter-segment revenue (i) |
- | - | ( |
) | - | |||||||||||||||||||||||
| Segment revenue |
( |
) |
||||||||||||||||||||||||||
| External cost of service |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||
| Inter-segment cost of service (i) |
( |
) | ( |
) | - | - | ( |
) | - | |||||||||||||||||||
| Segment cost of service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
| Gross profit |
( |
) |
||||||||||||||||||||||||||
| External selling expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
| Segment selling expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
| External administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||
| Inter-segment administrative expenses |
( |
) | ( |
) | - | - | ( |
) | - | |||||||||||||||||||
| Corporate expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
| Segment administrative expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
| Impairment losses on trade receivables |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
| Other income |
( |
) | ||||||||||||||||||||||||||
| Inter-segment other income |
- | - | ( |
) | ||||||||||||||||||||||||
| Other income |
( |
) |
||||||||||||||||||||||||||
| Segment operating profit (loss) |
( |
) |
||||||||||||||||||||||||||
| Share of profit of equity accounted investees, net of taxes |
- | - | - | |||||||||||||||||||||||||
| Exchange difference, net |
||||||||||||||||||||||||||||
| Interest expense, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
| Segment profit (loss) before tax |
( |
) |
||||||||||||||||||||||||||
| Other disclosures |
||||||||||||||||||||||||||||
| Depreciation and amortization |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
| Capital expenditure |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
| Segment assets |
( |
) |
( |
) |
||||||||||||||||||||||||
| Segment liabilities |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
In thousands of soles |
Reportable segments |
|||||||||||||||||||||||||||
Oncosalud Peru |
Healthcare services in Peru |
Healthcare services in Colombia |
Healthcare services in Mexico |
Total reportable segments |
Holding and eliminations |
Total | ||||||||||||||||||||||
2024 |
||||||||||||||||||||||||||||
External revenues |
- | |||||||||||||||||||||||||||
Inter-segment revenue (i) |
- | - | ( |
) | - | |||||||||||||||||||||||
Segment revenue |
( |
) |
||||||||||||||||||||||||||
External cost of service |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||
Inter-segment cost of service (i) |
( |
) | ( |
) | - | - | ( |
) | - | |||||||||||||||||||
Segment cost of service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Gross profit |
( |
) |
||||||||||||||||||||||||||
External selling expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Segment selling expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
External administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||
Inter-segment administrative expenses |
( |
) | ( |
) | - | - | ( |
) | - | |||||||||||||||||||
Corporate expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment administrative expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
Impairment losses on trade receivables |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Other income |
||||||||||||||||||||||||||||
Inter-segment other income |
- | - | ( |
) | - | |||||||||||||||||||||||
Other income |
( |
) |
||||||||||||||||||||||||||
Segment operating profit (loss) |
( |
) |
||||||||||||||||||||||||||
Share of profit of equity accounted investees, net of taxes |
- | - | - | |||||||||||||||||||||||||
Exchange difference, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Interest expense, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment profit (loss) before tax |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||
Other disclosures |
||||||||||||||||||||||||||||
Depreciation and amortization |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Capital expenditure |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment assets |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Segment liabilities |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
In thousands of soles |
Reportable segments |
|||||||||||||||||||||||||||
Oncosalud Peru |
Healthcare services in Peru |
Healthcare services in Colombia |
Healthcare services in Mexico |
Total reportable segments |
Holding and eliminations |
Total | ||||||||||||||||||||||
2025 |
||||||||||||||||||||||||||||
External revenues |
- | |||||||||||||||||||||||||||
Inter-segment revenue (i) |
- | - | ( |
) | - | |||||||||||||||||||||||
Segment revenue |
( |
) |
||||||||||||||||||||||||||
External cost of service |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||
Inter-segment cost of service (i) |
( |
) | ( |
) | - | - | ( |
) | - | |||||||||||||||||||
Segment cost of service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Gross profit |
( |
) |
||||||||||||||||||||||||||
External selling expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Segment selling expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
External administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||
Inter-segment administrative expenses |
( |
) | ( |
) | - | - | ( |
) | - | |||||||||||||||||||
Corporate expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment administrative expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
Impairment losses on trade receivables |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
Other income |
||||||||||||||||||||||||||||
Inter-segment other income |
- | - | ( |
) | - | |||||||||||||||||||||||
Other income |
( |
) |
||||||||||||||||||||||||||
Segment operating profit (loss) |
( |
) |
||||||||||||||||||||||||||
Share of profit of equity accounted investees, net of taxes |
- | - | - | |||||||||||||||||||||||||
Exchange difference, net |
( |
) | ||||||||||||||||||||||||||
Interest expense, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment profit (loss) before tax |
( |
) |
||||||||||||||||||||||||||
Other disclosures |
||||||||||||||||||||||||||||
Depreciation and amortization |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Capital expenditure |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment assets |
( |
) |
||||||||||||||||||||||||||
Segment liabilities |
||||||||||||||||||||||||||||
In thousands of soles |
Reportable segments |
|||||||||||||||||||||||||||
Oncosalud Peru |
Healthcare services in Peru |
Healthcare services in Colombia |
Healthcare services in Mexico |
Total reportable segments |
Holding and eliminations |
Total | ||||||||||||||||||||||
2024 |
||||||||||||||||||||||||||||
External revenues |
- | |||||||||||||||||||||||||||
Inter-segment revenue (i) |
- | - | ( |
) | - | |||||||||||||||||||||||
Segment revenue |
( |
) |
||||||||||||||||||||||||||
External cost of service |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||
Inter-segment cost of service (i) |
( |
) | ( |
) | - | - | ( |
) | - | |||||||||||||||||||
Segment cost of service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Gross profit |
( |
) |
||||||||||||||||||||||||||
External selling expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment selling expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||
External administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | |||||||||||||||
Inter-segment administrative expenses |
( |
) | ( |
) | - | - | ( |
) | - | |||||||||||||||||||
Corporate expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment administrative expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Impairment losses on trade receivables |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
Other income |
( |
) | ||||||||||||||||||||||||||
Inter-segment other income |
- | - | ( |
) | - | |||||||||||||||||||||||
Other income |
( |
) |
||||||||||||||||||||||||||
Segment operating profit (loss) |
( |
) |
||||||||||||||||||||||||||
Share of profit of equity accounted investees, net of taxes |
- | - | - | |||||||||||||||||||||||||
Exchange difference, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Interest expense, net |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment profit (loss) before tax |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||
Other disclosures |
||||||||||||||||||||||||||||
Depreciation and amortization |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Capital expenditure |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Segment assets |
( |
) |
||||||||||||||||||||||||||
Segment liabilities |
||||||||||||||||||||||||||||
| (i) | Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Peru S.A.C., a subsidiary providing healthcare services related to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Peru S.A.C., the revenue mainly consists of the insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance subsidiary that is also consolidated in Oncosalud Peru segment. In the segment consolidation process the related revenues from such healthcare services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third parties) of services incurred by Oncocenter Peru S.A.C. remains. |
18. |
Tax Matters |
| A. | Income tax is determined on a separate basis; it is not consolidated. According to Peruvian, Colombian, Mexican and Luxembourg current legal legislation, the income tax is paid based on the statutory financial statements and tax losses, additions, and deductions established. |
| B. | Income tax expense is recognized at an amount determined by multiplying the profit (loss) before taxes for the interim reporting period by management’s best estimate of the expected weighted-average annual income tax rate for the full fiscal year, adjusted for the tax effect of certain items recognized in full in the interim period. As such, the effective tax rate in the interim financial statements may differ from management’s estimate of the effective tax rate for the annual financial statements. The Group’s consolidated effective tax rate for the six months ended June 30, 2025 was |
| C. | The Group has recognized a deferred income tax asset related to the tax-loss carryforward of those subsidiaries where it is more likely than the tax-loss carryforward can be used to compensate future taxable net income. |
19. |
Financial Risk and Insurance Management |
A. |
Insurance risk |
In thousands of soles |
Frequency |
Frequency |
Average cost per patient |
Average cost per patient |
Combined |
Combined | ||||||||||||||||||||||
2025 |
||||||||||||||||||||||||||||
Change % |
+5% | +10% | +5% | +10% | +5% | +10% | ||||||||||||||||||||||
Cost of segment Oncosalud Peru |
||||||||||||||||||||||||||||
Frequency |
||||||||||||||||||||||||||||
Average cost per patient |
||||||||||||||||||||||||||||
#plan members |
||||||||||||||||||||||||||||
2024 |
||||||||||||||||||||||||||||
Change % |
+5% | +10% | +5% | +10% | +5% | +10% | ||||||||||||||||||||||
Cost of segment Oncosalud Peru |
||||||||||||||||||||||||||||
Frequency |
||||||||||||||||||||||||||||
Average cost per patient |
||||||||||||||||||||||||||||
#plan members |
||||||||||||||||||||||||||||
In thousands of soles |
Fluctuations in variables (%) |
2025 |
2024 | |||||||
Loss for the period |
Loss for the period | |||||||||
Frequency |
( |
( |
||||||||
Frequency |
( |
( |
||||||||
Average cost per patient |
( |
( |
||||||||
Average cost per patient |
( |
( |
||||||||
Combined |
( |
( |
||||||||
Combined |
( |
( |
||||||||
B. |
Market risk |
i. |
Exchange risk |
2025 |
2024 |
|||||||||||||||||||||||
In thousands of |
US$ |
COP |
MXN |
US$ |
COP |
MXN | ||||||||||||||||||
Assets: |
||||||||||||||||||||||||
Cash and cash equivalents |
||||||||||||||||||||||||
Trade accounts receivable |
||||||||||||||||||||||||
Other assets |
||||||||||||||||||||||||
Derivative financial instruments |
- | - | - | |||||||||||||||||||||
Liabilities |
||||||||||||||||||||||||
Loans and borrowings |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Lease liabilities |
( |
) | ( |
) | - | ( |
) | ( |
) | - | ||||||||||||||
Trade accounts payable |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Other accounts payable |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Derivative financial instruments |
( |
) | - | ( |
) | ( |
) | - | - | |||||||||||||||
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | |||||||||||||
(Liability) asset position, net |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||
In soles |
June 30, 2025 |
June 30, 2024 | ||||||
US$ 1 - Exchange rate - Buy (assets) |
||||||||
US$ 1 - Exchange rate - Sale (liabilities) |
||||||||
COP 1 - Exchange rate |
||||||||
MXN 1 - Exchange rate |
|
|
||||||
| June 30, 2025 | June 30, 2024 | |||||||||||||||||||
In thousands of soles |
Fluctuations in exchange rates (%) |
Profit or loss for the nine-month period |
Other comprehensive income |
Profit or loss for the nine-month period |
Other comprehensive income |
|||||||||||||||
Weakening |
( |
) | ( |
) | ||||||||||||||||
Weakening |
( |
) | ( |
) | ||||||||||||||||
Strengthening |
( |
) | ( |
) | ||||||||||||||||
Strengthening |
( |
) | ( |
) | ||||||||||||||||
ii. |
Interest rate risk |
C. |
Accounting classifications and fair values |
Carrying amount |
Fair value |
|||||||||||||||||||||||||||||||||||
In thousands of soles |
FVOCI – debt instruments |
Fair value hedging instruments |
Financial assets at amortized cost |
Other financial liabilities |
Total |
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||||||||||||||||
As of June 30, 2025 |
||||||||||||||||||||||||||||||||||||
Financial assets measured at fair value |
||||||||||||||||||||||||||||||||||||
Other investments |
- | - | - | - | - | |||||||||||||||||||||||||||||||
Derivative financial instruments |
- | - | - | - | - | |||||||||||||||||||||||||||||||
- |
- |
- |
||||||||||||||||||||||||||||||||||
Financial assets not measured at fair value |
||||||||||||||||||||||||||||||||||||
Cash and cash equivalents |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
Trade accounts receivable |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
Other assets (*) |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Financial liabilities measured at fair value |
||||||||||||||||||||||||||||||||||||
Derivative financial instruments |
- | - | - | - | - | |||||||||||||||||||||||||||||||
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||||
Financial liabilities not measured at fair value |
||||||||||||||||||||||||||||||||||||
Loans and borrowings |
- | - | - | - | - | |||||||||||||||||||||||||||||||
Lease liabilities |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
Trade accounts payable |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
Other accounts payable (**) |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||||
Carrying amount |
Fair value |
|||||||||||||||||||||||||||||||||||
In thousands of soles |
FVOCI – debt instruments |
Fair value hedging instruments |
Financial assets at amortized cost |
Other financial liabilities |
Total |
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||||||||||||||||
As of December 31, 2024 |
||||||||||||||||||||||||||||||||||||
Financial assets measured at fair value |
||||||||||||||||||||||||||||||||||||
Other investments |
- | - | - | - | - | |||||||||||||||||||||||||||||||
Derivative financial instruments |
- | - | - | - | - | |||||||||||||||||||||||||||||||
- |
- |
- |
||||||||||||||||||||||||||||||||||
Financial assets not measured at fair value |
||||||||||||||||||||||||||||||||||||
Cash and cash equivalents |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
Trade accounts receivable |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
Other assets (*) |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Financial liabilities measured at fair value |
||||||||||||||||||||||||||||||||||||
Derivative financial instruments |
- | - | - | - | - | |||||||||||||||||||||||||||||||
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||||
Financial liabilities not measured at fair value |
||||||||||||||||||||||||||||||||||||
Loans and borrowings |
- | - | - | - | - | |||||||||||||||||||||||||||||||
Lease liabilities |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
Trade accounts payable |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
Other accounts payable (**) |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||||
D. |
Measurement of fair values |
i. |
Valuation techniques and significant unobservable inputs |
Type |
Valuation technique |
Significant unobservable inputs |
Inter-relationship between significant unobservable inputs and fair value | |||
| Derivatives financial instruments (note 5) | For the Options: Garman–Kohlhagen: The fair value is determined using this model that treats foreign currencies as if they are equity securities that provide a known dividend yield, which uses the following inputs: Spot rate at the valuation date, strike price, implicit volatility, and risk-free rate in both currencies. For long-forward/swap: Interest rate parity: Consists of estimating the present value of the future profit (loss) generated by the forward/swap contract. The gain or loss is calculated as the difference between the forward exchange rate estimated according to the market and the strike. |
Not applicable | Not applicable |
E. |
Concentration of credit risk |
F. |
Liquidity risk |
◾ |
Auna S.A. can finance its current assets (accounts receivable, inventories and others) with current liabilities (accounts payable, deferred revenue and others). |
◾ |
Auna S.A. analyses the maturity of its debts to identify any refinancing required to maintain an appropriate debt structure. |
◾ |
Not considering growth capex (new hospitals, acquisitions, etc.), Auna has enough cash flow from operations to finance its maintenance capex, current debt service (interest and principal), dividends and a portion of growth capex. |
◾ |
Growth capex is financed mainly by long-term debt and cash flow from operations. In some cases, by capital contribution (for example: acquisition of PMLA and Hospital y Clínica OCA). |
◾ |
In addition, Auna has revolving credit lines of S/ |
◾ |
These credit lines are renewed every year. The interest rate applicable for the lines in Peru is a fixed rate that is agreed upon with the bank before the reception of the cash in Auna accounts and depends on the credit terms (up to |
In thousands of soles |
Carrying amount |
Contractual cash flows |
Less than 1 year |
From 1 to 2 years |
From 3 to 5 years |
More than 5 years |
||||||||||||||||||
As of June 30, 2025 |
||||||||||||||||||||||||
Trade accounts payable |
||||||||||||||||||||||||
Other accounts payable (*) |
||||||||||||||||||||||||
Loans and borrowings (**) |
||||||||||||||||||||||||
Lease liabilities |
||||||||||||||||||||||||
Derivative financial instruments |
||||||||||||||||||||||||
As of December 31, 2024 |
||||||||||||||||||||||||
Trade accounts payable |
||||||||||||||||||||||||
Other accounts payable (*) |
||||||||||||||||||||||||
Loans and borrowings (**) |
||||||||||||||||||||||||
Lease liabilities |
||||||||||||||||||||||||
Derivative financial instruments |
||||||||||||||||||||||||
20. |
Related Parties |
Transaction value |
||||||||||||||||||||||||
For three months ended |
For six months ended |
Outstanding balances |
||||||||||||||||||||||
In thousands of soles |
June 30, 2025 |
June 30, 2024 |
June 30, 2025 |
June 30, 2024 |
June 30, 2025 |
December 31, 2024 |
||||||||||||||||||
Sales of healthcare services and oncology plans |
||||||||||||||||||||||||
| Joint ventures | ||||||||||||||||||||||||
| Others | ||||||||||||||||||||||||
Cost of sales of healthcare services and oncology plans |
||||||||||||||||||||||||
| Joint ventures | ||||||||||||||||||||||||
| Associates | ||||||||||||||||||||||||
| Others | ||||||||||||||||||||||||
Administrative expenses |
||||||||||||||||||||||||
| Services provided by third parties (i) | - | |||||||||||||||||||||||
| Other management charges | ( |
) | ||||||||||||||||||||||
Selling expenses |
||||||||||||||||||||||||
| Services provided by third parties (ii) | ||||||||||||||||||||||||
Finance income, net |
||||||||||||||||||||||||
| Loans and related interest from related parties | - | - | - | - | ||||||||||||||||||||
| Loans and related interest to related parties | ( |
) | - | ( |
) | - | - | |||||||||||||||||
( |
) |
- |
( |
) |
- |
|||||||||||||||||||
i. |
Management expenses |
ii. |
Selling expenses |
21. |
Contingencies |
22. |
Share-Based Payments |
A. |
Description of share-based payment arrangements |
i. |
Restricted shares plan |
Grand date/ Directors entitled |
Number of shares in thousands |
Vesting conditions |
(In thousands of soles) |
|||||||||
2025 |
2024 |
|||||||||||
Award 2025 - Grant to Directors on |
- | |||||||||||
Award 2024 - Grant to Directors on |
- | |||||||||||
ii. |
Option and restricted stock unit plans |
Incentive plans / Vesting Commencement Date |
Number of options / shares in thousands |
Vesting conditions |
Contractual life of options / shares |
(In thousands of soles) 2025 |
||||||
Performance-Based Option Agreement on |
||||||||||
Long-Term Incentive Management on |
||||||||||
Restricted Stock Unit on |
||||||||||
B. |
Measurement of grant date fair values |
Incentive plans |
Year |
Methodology of fair value |
Grace period |
Number of options / shares in thousands |
Annual volatility |
Risk-free rate |
Weighted average of fair value of options / shares (in soles) 2025 |
Vesting status | ||||||||
| Performance-Based Option Agreement |
2024 | Binomial | 21/03/2024 to 21/03/2027 |
Partially vested | ||||||||||||
| Long-Term Incentive Management |
2024 | Black Scholes |
21/03/2024 to 21/03/2028 |
Partially vested | ||||||||||||
| Restricted Stock Units |
2024 | Market value | 21/03/2024 to 21/03/2027 |
- | - | Partially vested |
23. |
Subsequent Events |
24. |
Material Accounting Policies |
25. |
Standards Issued but Not Yet Effective |
Effective date |
New standards or amendments | |
January 1, 2025 |
◾ Lack of Exchangeability – Amendments to IAS 21 |
Effective date |
New standards or amendments | |
| January 1, 2026 | ◾ Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7◾ Contracts Referencing Nature-dependent Electricity—Amendments to IFRS 9 and IFRS 7◾ Annual Improvements to IFRS Accounting Standards – Volume 11 |
Effective date |
New standards or amendments | |
| January 1, 2027 | ◾ IFRS 18 - Presentation and Disclosure in Financial Statements◾ IFRS 19 - Subsidiaries without Public Accountability: Disclosures | |
Available for optional adoption/ effective date deferred indefinitely |
◾ Sale or Contribution of Assets between an Investor and its Associate or Joint Venture – Amendments to IFRS 10 and IAS 28. |